Our approach provides a comprehensive solution to the current limitations in Alzheimer’s diagnosis by offering F-18 labeled drugs that effectively target Tau protein without compromising their biological activity, advancing both diagnostic and therapeutic strategies for AD. This evidence concerns the gene MAPT and Alzheimer disease.